
Antibody drugs have become an increasingly important class of therapeutics for a wide range of diseases. In this article, we will introduce the top 10 antibody drugs that have been approved by regulatory agencies from 1980 to 2022 and provide some information about their development history and the diseases they are used to treat.
Humira (adalimumab): Humira was approved by the FDA in 2002 and is used to treat rheumatoid arthritis, psoriasis, and other autoimmune disorders. It was the first fully human antibody drug approved by the FDA.
Keytruda (pembrolizumab): Keytruda was approved by the FDA in 2014 and is used to treat melanoma, lung cancer, and other cancers. It was the first PD-1 inhibitor approved by the FDA.
Herceptin (trastuzumab): Herceptin was approved by the FDA in 1998 and is used to treat HER2-positive breast cancer. It was the first monoclonal antibody drug approved for cancer treatment.
Remicade (infliximab): Remicade was approved by the FDA in 1998 and is used to treat Crohn's disease, rheumatoid arthritis, and other autoimmune disorders. It was the first anti-TNF-alpha antibody drug approved by the FDA.
Rituxan (rituximab): Rituxan was approved by the FDA in 1997 and is used to treat non-Hodgkin's lymphoma and other blood cancers. It was the first monoclonal antibody drug approved for cancer treatment.
Opdivo (nivolumab): Opdivo was approved by the FDA in 2014 and is used to treat melanoma, lung cancer, and other cancers. It was the first PD-1 inhibitor approved by the FDA.
Avastin (bevacizumab): Avastin was approved by the FDA in 2004 and is used to treat colon cancer, lung cancer, and other cancers. It was the first anti-angiogenic antibody drug approved by the FDA.
Lucentis (ranibizumab): Lucentis was approved by the FDA in 2006 and is used to treat macular degeneration, diabetic retinopathy, and other eye diseases. It was the first antibody drug approved for ophthalmic use.
Stelara (ustekinumab): Stelara was approved by the FDA in 2009 and is used to treat psoriasis, psoriatic arthritis, and Crohn's disease. It was the first interleukin inhibitor approved by the FDA.
Tecentriq (atezolizumab): Tecentriq was approved by the FDA in 2016 and is used to treat bladder cancer, lung cancer, and other cancers. It was the first PD-L1 inhibitor approved by the FDA.
At Biointron, we offer high-quality recombinant antibody production services that can help researchers and biotech companies develop antibody-based drugs for various diseases. Our team of experts can provide customized solutions that meet your specific research needs. Contact us to learn more about our services and how we can help accelerate your research and drug development projects.
In this article, we explore the major trends shaping the future of targeted canc……
Site-specific conjugation limits payload attachment to defined positions on the ……
Affinity maturation can improve binding to the intended target, but it can also ……
ADC development is no longer limited to the antibody-linker-toxin model. The fie……
Our website uses cookies to improve your experience. Read our Privacy Policy to find out more.
Biointron uses cookies and similar technologies to ensure proper website functionality, understand how visitors use our website, and improve our content and services. Necessary cookies are enabled by default.
By clicking “Accept All”, you agree to the use of all cookies, including analytics and optional cookies that help us understand website usage and improve user experience. By clicking “Reject Non-Essential”, only necessary cookies will be used.
You may manage or change your cookie preferences at any time by clicking “Cookie Settings” at the bottom of the website.
For more information about how we use cookies and process personal data, please review our Privacy Policy.



